EMEA-002698-PIP03-22 - paediatric investigation plan

Eftilagimod alpha

Key facts

• Active substance:
  Eftilagimod alpha
• Therapeutic area:
  Oncology
• Decision number:
  P/0026/2023
• PIP number:
  EMEA-002698-PIP03-22
• Pharmaceutical form(s):
  All pharmaceutical forms
• Condition(s) / indication(s):
  Treatment of non-small cell lung cancer
• Route(s) of administration:
  All routes of administration
• Compliance check done:
  No

Decision

P/0026/2023 : EMA decision of 31 January 2023 on the granting of a product specific waiver for eftilagimod alpha (EMEA-002698-PIP03-22)

Reference Number: EMA/18865/2023